April 5, 2016 — IBA (Ion Beam Applications SA) has recently received CE mark authorization of its new supra conducting accelerator. The accelerator is the latest development of the Proteus One, IBA’s compact intensity modulated proton therapy (IMPT) system, that needed approval from competent authorities.
CE Marking was a necessary step towards the acceptance of the first Proteus One in Europe, which is located at the Centre Antoine-Lacassagne (CAL) in Nice, France. In less than three months, in June 2016, the center will be fully accepted with all necessary certifications.
IBA has signed another five additional contracts to provide Proteus One in Europe, with a total of 12 centers sold worldwide.
For more information: www.iba-worldwide.com
April 10, 2026 
